January 11, 2022
The Chan Zuckerberg Biohub announced today (Jan. 11) the second cohort of scientists to be named CZ Biohub Investigators, 21 of whom are UC Berkeley faculty members. Of these 21 Berkeley faculty members, nine are QB3-Berkeley faculty affiliates. The investigator competition, open to faculty members at Stanford University, UC San Francisco and Berkeley, awards $1 million…
December 15, 2021
UC Berkeley is partnering with UC San Francisco and Stanford University as founding scientific members of a new institute that aims to accelerate breakthroughs in complex diseases. The Arc Institute was officially launched today (Dec. 15) with the goal of developing a new model for collaborative research that brings together world-class research with unconstrained funding…
December 09, 2021
David Schaffer has been named a fellow of the National Academy of Inventors, the highest professional distinction accorded solely to academic inventors.
September 27, 2021
QB3-Berkeley faculty affiliate Jay Keasling has been named a Distinguished Scientist Fellow by the U.S. Department of Energy’s Office of Science. The renowned synthetic biologist will be given $1 million in funding to support bioenergy and bioproduct innovation.
September 23, 2021
The Howard Hughes Medical Institute (HHMI), the nation’s largest biomedical research foundation, announced the appointment of 33 American scientists as investigators, and three of them are from the University of California, Berkeley.
September 16, 2021
Elçin Ünal and Gloria Brar, associate professors of molecular and cell biology, have been named 2021 Innovation Fund investigators by the Pew Charitable Trusts.
June 01, 2021
The lack of widely available testing has been a major roadblock to containing a virus that people can spread without showing, or even feeling, any symptoms. A COVID-19 test is Dan Fletcher’s latest transformation of cell phones into mobile diagnostic tools.
April 01, 2021
CRISPR-Cas9 treatment of sickle cell disease has been approved for clinical trials by the U.S. Food and Drug Administration. Researchers will now test CRISPR-Cas9 on humans to directly correct the mutation in the beta-globin gene responsible for sickle cell disease.